基于SSA分类器的阿尔茨海默氏病查研究
Zihao Qi1, Zhigang Li2, Peng Shan2
1School of Control Engineering, Northeastern University at Qinhuangdao, Qinhuangdao 066003, China.
概括
一个新的诊断框架使用等离子体光谱和机器学习进行阿尔茨海默病 (AD) 查. 优化的算法显著提高了准确性和灵敏度,显示了作为一种最小侵入性AD检测工具的潜力.
科学领域:
- 生物医学工程 生物医学工程
- 频谱学是一种光谱学.
- 机器学习 机器学习
背景情况:
- 阿尔茨海默病 (AD) 是最常见的神经退行性疾病,影响了65岁及以上的10%的人.
- 早期和准确的诊断对于AD的有效管理和治疗至关重要.
研究的目的:
- 开发和验证用于阿尔茨海默病 (AD) 查的新型诊断框架.
- 为了整合等离子体减弱总反射里埃变换红外光谱 (ATR-FTIR) 与先进的机器学习算法.
- 为了优化机器学习分类器性能,使用修改后的Sparrow搜索算法 (GSSA).
主要方法:
- 使用ATR-FTIR光谱学分析了血样本.
- 使用了四个机器学习分类器 (SVM,物流回归,XGBoost,LDA).
- 使用GSSA优化了分类器,并与标准的Sparrow搜索算法 (SSA) 和贝叶斯方法进行了比较.
- 评估了包括准确性,敏感性和特异性在内的性能指标.
主要成果:
- 优化GSSA的分类器显著超过了标准的SSA和贝叶斯方法.
- 该GSSA-XGBoost模型实现了最高的精度 (88.51%),灵敏度 (95.35%) 和特异性 (81.82%).
- GSSA进一步提高了对97.67% (SVM/LDA) 的敏感性和对81.82% (XGBoost) 的特异性.
结论:
- 拟议的ATR-FTIR光谱和GSSA优化的机器学习框架显示出作为阿尔茨海默病的最小侵入性查工具的巨大潜力.
- 这种综合方法推进了光谱生物标记物的发现,并证明了算法优化的有效性.
- 由GSSA优化的XGBoost为AD诊断性能提供了最佳的平衡.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.1K
08:43Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
7.8K
相关概念视频
Alzheimer's Disease: Overview
396
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
396
Alzheimer's Disease: Treatment
136
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
136
